An increasing amount of research is devoted to blocking the PD-1/PD-L1 interaction by applying small-molecule compounds to address these drawbacks of antibody drugs, opening a new avenue for tumor immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.